nevirapine has been researched along with Erythema in 3 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risk for disease progression did not differ between the two groups (relative hazard of the triple-combination group, 1." | 2.68 | Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco ( Basgoz, N; D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Liou, SH; Myers, M; Niu, M; Sommadossi, JP; Timpone, J, 1996) |
| "Nevirapine was dosed according to the manufacturer's guidelines." | 1.32 | Nevirapine use in HIV-1-infected children. ( Ball, C; Dumont, G; Gibb, DM; Lyall, H; Novelli, V; Sharland, M; Tudor-Williams, G; Verweel, G; Walters, S; Wilkins, E, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verweel, G | 1 |
| Sharland, M | 1 |
| Lyall, H | 1 |
| Novelli, V | 1 |
| Gibb, DM | 1 |
| Dumont, G | 1 |
| Ball, C | 1 |
| Wilkins, E | 1 |
| Walters, S | 1 |
| Tudor-Williams, G | 1 |
| D'Aquila, RT | 1 |
| Hughes, MD | 1 |
| Johnson, VA | 1 |
| Fischl, MA | 1 |
| Sommadossi, JP | 1 |
| Liou, SH | 1 |
| Timpone, J | 1 |
| Myers, M | 1 |
| Basgoz, N | 1 |
| Niu, M | 1 |
| Hirsch, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine[NCT00000770] | Phase 2 | 400 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for nevirapine and Erythema
| Article | Year |
|---|---|
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Com | 1996 |
2 other studies available for nevirapine and Erythema
| Article | Year |
|---|---|
Nevirapine use in HIV-1-infected children.
Topics: Adolescent; Anti-HIV Agents; Body Height; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Secti | 2003 |
Nevirapine triple combo results released.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combinat | 1995 |